B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received July 23, 2020
- Accepted in final form January 12, 2021
- First Published March 11, 2021.
Author Disclosures
- Sabine Tacke, MSc (sabine.tacke{at}fau.de),
- Stefan Braune, MD (sbraune{at}neurotransdata.com),
- Damiano M. Rovituso, PhD (damianorovituso{at}yahoo.de),
- Tjalf Ziemssen, MD (tjalf.ziemssen{at}uniklinikum-dresden.de),
- Paul V. Lehmann, MD (paul.lehmann{at}immunospot.com),
- Heidi Dikow, MSc (hdikow{at}neurotransdata.com),
- Arnfin Bergmann, MD (abergmann{at}neurotransdata.com) and
- Stefanie Kuerten, MD, PhD
- Sabine Tacke, MSc (sabine.tacke{at}fau.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Braune, MD (sbraune{at}neurotransdata.com),
NONE
NONE
1) Biogen 2) NeuroTransData
NONE
NONE
NONE
NONE
1) NeuroTransData
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Damiano M. Rovituso, PhD (damianorovituso{at}yahoo.de),
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biorasi GmbH (CRO), CTA/CRA, >1 year (Apr 2019 - ongoing) (2) Uniklinik Würzburg, Postdoc, < 1 year (Dec 2017 - Jul 2018) (3) University of Würzburg, Postdoc, 1 year (Aug 2016 - Oct 2017) (employment related to this manuscript)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tjalf Ziemssen, MD (tjalf.ziemssen{at}uniklinikum-dresden.de),
(1) Bayer Healthcare (2) Biogen Idec (3) Novartis (4) Merck Serono (5) Teva (6) Genzyme (7) Roche (8) Celgene; all commercial
NONE
Speaker honorarium for all commercial entities (1) Bayer Healthcare (2) Biogen Idec (3) Sanofi Genzyme (4) Celgene (5) Roche (6) Novartis (7) Teva (8) Almirall (o) Merck
(1) BMC Neurology, Section editor, demyelinating disorders, since 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen Idec (2) Sanofi Genzyme (3) Novartis (4) Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paul V. Lehmann, MD (paul.lehmann{at}immunospot.com),
NONE
NONE
NONE
NONE
I am co-inventor on an issued patent that uses B cell ELISPOT to diagnose Multiple Sclerosis
NONE
I am the Founder and CEO of CTL, a company that focuses on ELISPOT-based immune diagnostic.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heidi Dikow, MSc (hdikow{at}neurotransdata.com),
NONE
NONE
NONE
NONE
NONE
NONE
NeuroTransData GmbH, Data Scientist, 3 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Arnfin Bergmann, MD (abergmann{at}neurotransdata.com) and
(1) NeuroTransData GmbH
NONE
(1) Novartis (2) Servier
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefanie Kuerten, MD, PhD
(1) Novartis
NONE
(1) Novartis (2) Sanofi Genzyme (3) Roche
(1) International Journal of Molecular Sciences, Associate Editor, 2020-now (2) International Journal of Molecular Sciences, Special Issue Guest Editor, 2020 (3) BMC Neurology, Associate Editor, 2013-now
(1) ELISPOT technology for the detection of autoimmune responses
NONE
NONE
NONE
NONE
NONE
NONE
(1) NeuroTransData GmbH
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute of Anatomy and Cell Biology (S.T., D.M.R., S.K.), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany; NeuroTransData (S.B., H.D., A.B.), Neuburg an der Donau, Germany; Department of Neurology (T.Z.), Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; and Research and Development Department (P.V.L.), Cellular Technology Limited, Shaker Heights, OH.
- Correspondence
Dr. Kuerten stefanie.kuerten{at}uni-bonn.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MSGisella Guerrera, Serena Ruggieri, Mario Picozza et al.Neurology: Neuroimmunology & Neuroinflammation, August 17, 2020 -
Article
Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MSDarius Häusler, Zivar Hajiyeva, Jan W. Traub et al.Neurology: Neuroimmunology & Neuroinflammation, March 17, 2020 -
Articles
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disabilityK. P. Johnson, B. R. Brooks, J. A. Cohen et al.Neurology, March 01, 1998 -
Articles
Magnetic resonance imaging and treatment effects of multiple sclerosis therapeuticsThomas P. Leist, Steven Marks et al.Neurology, December 28, 2009